Skip to main content

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed · Phase 2 · NCT04658472

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy

At a glance

Research payments reported, 2025
$41,812
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
98

About the trial

Sponsor
Bioverativ, a Sanofi company
Tested
SAR445088 (IV) (drug), SAR445088 (SC) (drug)
Dates
Started 2021-04-28; completion 2025-10-01
Results posted
Not yet

Primary Objectives: * Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive * Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: * Part A: * Safety and tolerability of SAR445088 in CIDP * Immunogenicity of SAR445088 * Efficacy of SAR445088 with overlapping SOC (SOC-Treated group) * Part B: * Durability of efficacy during long-term treatment with SAR445088 in CIDP * Long-term immunogenicity of SAR445088 in CIDP

From ClinicalTrials.gov, last updated 2025-10-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $41,812 in research payments for this study in 2025 (12 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • University of Kansas Medical Center Research Inst Inc $15,028
  • The Trustees of Columbia University in The City of New York $13,230
  • Regents of the University of Minnesota $9,000
  • Uci Health-Orange, CA $4,554

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.